Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Element Biosciences, Sema4, OriCiro Genomics, More

Element Biosciences: Brian Stolz, Diana King, Jordan Neysmith

Element Biosciences has added several new members to its leadership team. Brian Stolz has joined the DNA sequencing firm as chief people officer, Diana King as VP of customer service, and Jordan Neysmith as VP of engineering.

Stolz comes to Element from BridgeBio, where he was chief operating officer. Prior to that, he was chief people officer at Activision Blizzard, and before that, he held executive roles at Bausch Health and McKinsey. He has a B.S. in finance from Georgetown University and an MBA from Harvard University.

King was previously chief business development officer at medical imaging firm Multi. Before that, she held service and support leadership roles at Agfa Radiology Solutions, Prime Healthcare, and GE Healthcare. She holds a B.S. in computer engineering and an MBA from Texas A&M University.

Neysmith joins Element from Bruker Nano Surfaces, where he was senior director of development and engineering. Before that, he held engineering leadership positions at Carl Zeiss Meditec, Earlens, and Second Sight Medical Products. He holds a B.S. in mechanical engineering from Yale University and an M.S. in mechanical engineering from the Georgia Institute of Technology.

Sema4: Eli Casdin, Emily Leproust, Jason Ryan, Nat Turner

As part of its merger with special purpose acquisition company CM Life Sciences, Sema4 has appointed four new directors to its board: Eli Casdin, chief investment officer of Casdin Capital; Emily Leproust, CEO of Twist Bioscience; Jason Ryan, former chief operating officer and CFO of Magenta Therapeutics and former CFO of Foundation Medicine; and Nat Turner, cofounder of Flatiron Health.

OriCiro Genomics: Shige Sasaki, Nasir Kato Bashiruddin

Tokyo-based synthetic biology firm OriCiro Genomics has appointed Shigemasa (Shige) Sasaki as chief operating officer and chief business officer, and Nasir Kato Bashiruddin as chief technology officer.

Prior to joining OriCiro, Sasaki was president of the Japanese subsidiary of Unchained Labs, a US-based research tools company. Before that, he was Asia Pacific marketing director at GE Healthcare. He holds a B.S. in bioengineering from Fukui Prefectural University.

Bashiruddin used to be director of the platform innovation group at PeptiDream, a peptide drug discovery firm. He holds a Ph.D. in chemistry from the University of Tokyo and a B.S. in biology from the University of Washington.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.